Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18872 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Anne Bruun Rovsing und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dagmar Marshalls Fond, Danmarks Frie Forskningsfond, Fabrikant Einar Willumsens Mindelegat.
Abstract (Originalsprache)
The frontline therapy R‐CHOP for patients with diffuse large B‐cell lymphoma (DLBCL) has remained unchanged for two decades despite numerous Phase III clinical trials investigating new alternatives. Multiple large studies have uncovered genetic subtypes of DLBCL enabling a targeted approach. To further pave the way for precision oncology, we perform genome‐wide CRISPR screening to uncover the cellular response to one of the components of R‐CHOP, vincristine, in the DLBCL cell line SU‐DHL‐5. We discover important pathways and subnetworks using gene‐set enrichment analysis and protein–protein interaction networks and identify genes related to mitotic spindle organization that are essential during vincristine treatment. The inhibition of KIF18A, a mediator of chromosome alignment, using the small molecule inhibitor BTB‐1 causes complete cell death in a synergistic manner when administered together with vincristine. We also identify the genes KIF18B and USP28 of which CRISPR/Cas9‐directed knockout induces vincristine resistance across two DLBCL cell lines. Mechanistic studies show that lack of KIF18B or USP28 counteracts a vincristine‐induced p53 response suggesting that resistance to vincristine has origin in the mitotic surveillance pathway (USP28‐53BP1‐p53). Collectively, our CRISPR screening data uncover potential drug targets and mechanisms behind vincristine resistance, which may support the development of future drug regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
- Lars Bolund Institute of Regenerative Medicine, BGI-Qingdao, BGI-Shenzhen, Shenzhen, China.
- Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
ORCID-Profile: Anne Bruun Rovsing, Emil Aagaard Thomsen, Yonglun Luo, Jacob Giehm Mikkelsen
Förderung
- Dagmar Marshalls Fond
- Danmarks Frie Forskningsfond
- Fabrikant Einar Willumsens Mindelegat
- Helga og Peter Kornings Fond
Zitieren
APA
Rovsing, A. B., Thomsen, E. A., Nielsen, I., Skov, T. W., Luo, Y., Dybkaer, K., & Mikkelsen, J. G. (2023). Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. British Journal of Haematology. https://doi.org/10.1111/bjh.18872
Vancouver
Rovsing AB, Thomsen EA, Nielsen I, Skov TW, Luo Y, Dybkaer K, et al. Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28. British Journal of Haematology. 2023. doi:10.1111/bjh.18872
BibTeX
@article{Rovsing2023,
author = {Rovsing, Anne Bruun and Thomsen, Emil Aagaard and Nielsen, Ian and Skov, Thomas Wisbech and Luo, Yonglun and Dybkaer, Karen and Mikkelsen, Jacob Giehm},
title = {Resistance to vincristine in DLBCL by disruption of p53‐induced cell cycle arrest and apoptosis mediated by KIF18B and USP28},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18872}
}
EUVIMED